Patent ID: 8361722
Filing Date: 2013-01-29
Classification: A61P,C07H,C12N,C12Q,G01N

Abstract:
1. A method of determining whether a subject has, or is at risk for developing, acute lymphomic leukemia (ALL), wherein the method comprises: extracting from the subject a test sample, wherein the test sample comprises: at least miR-221gene product; and blood, tissue and/or bone marrow having, or suspected of having, leukemic cells and/or leukemic lymphoblasts; measuring the level of the at least miR-221 gene product in the test sample; determining whether the subject has, or is at risk for developing, ALL by comparing the level of the at least miR-221 gene product in the test sample to the level of a corresponding miR gene product in a control sample, correlating an increase in the level of the at least miR-221 gene product in the test sample, relative to the level of the corresponding miR gene product in the control sample, as being indicative of a diagnosis of the subject either having, or being at risk for developing, ALL.